Sign In
Buy VRCA
$5.22
-0.0400 (-0.760%)
At Close: Jul 31, 2026
Verrica Pharmaceuticals Announces that YCANTH™ Receives New Chemical Entity Status and Orange Book Listing from the FDA
07:30am, Tuesday, 26'th Mar 2024
NCE status provides a minimum of five years of regulatory exclusivity The Company's U.S. patents and pending patent applications related to YCANTH™ are projected to expire between 2034 and 2041, exc
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
12:22pm, Thursday, 29'th Feb 2024
Verrica Pharmaceuticals Inc. (VRCA) Q4 2023 Earnings Call Transcript
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2023 Financial Results
07:30am, Thursday, 29'th Feb 2024
– Reports YCANTH™ revenue of $1.9M for fourth quarter and $4.7M for full year 2023 – – Over 200 million lives now covered on commercial insurance and managed Medicaid plans – – Conference
Verrica Pharmaceuticals Announces Participation in the TD Cowen 44th Annual Healthcare Conference
07:30am, Tuesday, 27'th Feb 2024
WEST CHESTER, Pa., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski
WEST CHESTER, Pa., Feb. 22, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski
Verrica Pharmaceuticals Files Lawsuit Against Canadian Drug Manufacturer for False Advertising and Unfair Competition
07:30am, Monday, 05'th Feb 2024
Lawsuit alleges false and misleading advertising and promotion of unapproved cantharidin-containing drugs by Dormer Laboratories in violation of federal and state law
Verrica Pharmaceuticals Receives Permanent J-Code (J7354) for YCANTH™ from Centers for Medicare and Medicaid Services
07:30am, Monday, 29'th Jan 2024
WEST CHESTER, Pa., Jan. 29, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski
7 Potential Short-Squeeze Stocks Poised for Rapid Gains
07:44pm, Monday, 22'nd Jan 2024
You want potential short-squeeze stocks that could have the bears running for cover? Great, we got ‘em right here!
There are approximately 3-4 million diagnoses of basal cell carcinomas in the U.S. each year, with a high unmet need for new treatment options
WEST CHESTER, Pa., Jan. 04, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski
Verrica Pharmaceuticals Announces Specialty Pharmacy Partnership Agreement with Walgreens to Distribute YCANTH™
07:30am, Wednesday, 03'rd Jan 2024
WEST CHESTER, Pa., Jan. 03, 2024 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski
Here's What Insiders Are Buying to Wrap Up the Year
10:10am, Sunday, 31'st Dec 2023
As the year wound to a close, biotechs were in focus among the notable insider purchases.
Buffett, Dollar Tree Purchases Highlight Pre-Christmas Insider Buying
09:03am, Saturday, 23'rd Dec 2023
Ahead of the holiday weekend (and the end of the year), Berkshire Hathaway made another big buy of the Oracle of Omaha's favorite oil and gas exploration and production company.
Why Is Verrica Pharmaceuticals (VRCA) Stock Up 40% Today?
01:49pm, Friday, 15'th Dec 2023
Shares of Verrica Pharmaceuticals (NASDAQ: VRCA ) skyrocketed on Friday thanks to positive late-stage clinical trial results. Specifically, Verrica — along with its development and commercialization
Verrica Pharmaceuticals to Provide a Corporate Update and Report Third Quarter Financial Results on November 9, 2023
07:00am, Wednesday, 25'th Oct 2023
WEST CHESTER, Pa., Oct. 25, 2023 (GLOBE NEWSWIRE) -- Verrica Pharmaceuticals Inc. (“Verrica” or “the Company”) (Nasdaq: VRCA), a dermatology therapeutics company developing medications for ski
